Hunter Syndrome Treatment Market Dynamics: The Role of Regulatory Changes on Growth

 The global hunter syndrome treatment market size is expected to reach a value of USD 1.78 billion by 2030, expanding at a CAGR of 5.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. High unmet needs, robust pipeline, increasing awareness about this rare disease and growing R&D activities for the development of novel therapies are expected to drive market growth over the forecast period.

Hunter syndrome, also referred as mucopolysaccharidosis type II (MPS II), is a rare genetic disorder caused by the missing or malfunctioning iduronate-2-sulfatase enzyme. According to the data published by the National Institute of Neurological Disorders and Stroke, MPS II syndrome occurs in around 1 in every 100,000 to 150,000 male births.

Presently, there are no approved curative therapies for the treatment of Hunter syndrome. The available treatment options such as enzyme replacement therapy (ERT) and hematopoietic stem cell transplant (HSCT) are focused on providing symptomatic relief and management of complications associated with disease progression. Shire plc’s Elaprase (idursulfase) is the only key drug available for the treatment of Hunter syndrome worldwide, with GC Pharma’s Hunterase (idursulfase beta) being approved only in South Korea.

Gather more insights about the market drivers, restrains and growth of the Global Hunter Syndrome Treatment Market

 

Key players are focused on extensive R&D activities for product development and gaining approval as novel therapies. Launch of such novel therapies in the near future is expected to significantly fuel the Hunter syndrome treatment market growth. For instance, in May 2018, REGENXBIO Inc. received the U.S. FDA’s Fast Track designation for its novel drug candidate RGX-121, indicated for the disease treatment.

Hunter Syndrome Treatment Market Report Highlights

  • The intravenous segment led the market and accounted for the largest revenue share of 72.3% in 2024 attributed to its established effectiveness in delivering enzyme replacement therapies (ERT).
  • Enzyme replacement therapy (ERT) led the market and accounted for the largest revenue share of 57.3% in 2024 driven by its ability to address the deficiency of the enzyme iduronate-2-sulfatase.
  • Hospitals held the dominant position in the market, accounting for the largest revenue share of 63.1% in 2024 attributed to their capacity to provide comprehensive care and advanced medical resources.
  • North America hunter syndrome treatment market dominated the global market and accounted for the largest revenue share of 37.5% in 2024 attributed to a combination of advanced healthcare infrastructure and increasing awareness of rare diseases.

Key Hunter Syndrome Treatment Company Insights

Some key players in the market include Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd, Abbott, Medtronic, and others. These companies adopt strategies, including collaborations and partnerships, to stay competitive advantage. Furthermore, new product launches are pivotal; for instance, REGENXBIO’s RGX-121 has garnered attention for its potential in treating the condition. These strategies, combined with ongoing research and development efforts, drive innovation and improve treatment options for patients with Hunter syndrome.

  • Abbott develops innovative medical Enzyme Replacement Therapy (ERT), diagnostics, nutrition products, and branded generic pharmaceuticals. The company produces diagnostic tools that aid in the early detection and management of rare diseases. Their extensive portfolio includes advanced laboratory instruments and tests that facilitate accurate diagnosis, enabling healthcare providers to implement timely treatment strategies for patients with Hunter syndrome.
  • Medtronic specializes in developing Enzyme Replacement Therapy (ERT) and therapies for various medical conditions, including those affecting the cardiovascular, diabetes, and neurological segments. The company’s expertise in advanced drug delivery systems can be crucial in administering therapies such as enzyme replacement therapy. The company is committed to enhancing patient outcomes through innovative solutions that improve the delivery and efficacy of treatments for rare diseases such as Hunter syndrome.

List of Key Players of Hunter Syndrome Treatment Market

  • Takeda Pharmaceutical Company Limited
  • Hoffmann-La Roche Ltd
  • Abbott
  • Denali Therapeutics
  • Medtronic
  • Johnson & Johnson Services, Inc.
  • GSK Plc.
  • Bayer AG
  • Zimmer Biomet
  • Stryker Corporation
  • Homology Medicines, Inc.
  • Novartis AG

Order a free sample PDF of the Hunter Syndrome Treatment Market Intelligence Study, published by Grand View Research.

Comments

Post a Comment

Popular posts from this blog

Drug Addiction - Pipeline Review, H1 2017 Market Overview and trends research report

Radiant insights, inc latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction - Pipeline Review, H1 2017, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape. Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body or clothes. Report Highlights Radiant insights, inc Pharmaceutical and Healthcare latest pipeline guide Drug Addiction - Pipeline Review, H1 2017, p...
Read more

All Countries Dialyzer Industry 2013-2028 - Market Size, Share, Outlook, Growth, Key Players and Forecast

The global Dialyzer market was valued at $XX million in 2018, and Radiant Insights, Inc analysts predict the global market size will reach $XX million by the end of 2028, growing at a CAGR of XX% between 2018 and 2028. This report provides detailed historical analysis of global market for Dialyzer from 2013-2018, and provides extensive market forecasts from 2019-2028 by region/country and subsectors. It covers the sales volume, price, revenue, gross margin, historical growth and future perspectives in the Dialyzer market. Download Free Sample Report @ https://www.radiantinsights.com/research/2013-2028-report-on-global-dialyzer-market/request-sample Leading players of Dialyzer including: • Fresenius Medical Care • Baxter • Nipro • Asahi Kasei • Toray • B.Braun • Nikkiso • Medtronic • Kawasumi • Medica • Wego • Lengthen • Peony Medical • Chengdu OCI • Bain Medical Equipment Market split by Type, can be divided into: • Flat Type Dialyzer • Coil Tube Dialyzer • Ho...
Read more

Insights into the Medical Waste Disposal Category: A Comprehensive Procurement Intelligence Report

  Medical Waste Disposal Category Overview The medical waste disposal category is anticipated to grow at a CAGR of 6.0% from 2023 to 2030. Appropriate disposal of medical trash is the key challenge for healthcare providers across the globe. Rising awareness about the benefits of proper medical waste management for treatment, recycling, and disposal of medical trash has boosted the growth of the category. According to the World Health Organization Study Report 2022, countries with low income generate over 0.2 kg of medical trash per day per hospital bed, whereas countries with high income generate hazardous waste of up to 0.5 kg per hospital bed each day. Moreover, rising government initiatives and strict rules and regulations for waste management are also expected to drive the category. For instance, in December 2022, an MOU was signed between the Center for Health Environment Research and Development and Can Tho Central General Hospital under USAID’s Reducing Pollution Project. T...
Read more